388MO Preliminary safety and efficacy of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in combination with nivolumab and mFOLFOX in metastatic gastroesophageal carcinoma (mGEC)
Titel:
388MO Preliminary safety and efficacy of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in combination with nivolumab and mFOLFOX in metastatic gastroesophageal carcinoma (mGEC)
Auteur:
Klempner, S.J. Dayyani, F. Kratz, J. Kim, S. Xu, C. Ahlers, C.M. Liu, X. Chung, J-K. Sabbatini, P. Dennis, P.A. Lee, S. Jeon, J. Ku, G.